C-Reactive Protein Test (CRP) Market Size, Share, Industry, Forecast and outlook (2024-2031)

C - Reactive Protein Test (CRP) Market is Segmented By Assay Type( Immunoturbidimetric Assay, ELISA, Clinical, Nonclinical, Chemiluminescence Immunoassay, Others), By Detection Type(hs-CRP, cCRP, Conventional CRP), By Disease Area(Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Others), By End-User(Clinics, Hospitals, Laboratories, Diagnostic Center, Others)and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

C - Reactive Protein Test (CRP) Market Overview

The Global C - Reactive Protein Test (CRP) Market is estimated to reach at a CAGR of 1.8% during the forecast period (2023-2030).  C-reactive protein (CRP) is a ring-shaped protein observed in blood plasma, whose levels rise in response to inflammation. The C-reactive protein (CRP) assay kit is used to detect the C-reactive protein in human serum and plasma samples.

C - Reactive Protein Test (CRP) Market Summary and Scope

To Know More: Download Sample

C - Reactive Protein Test (CRP) Market Dynamics and Trends

The growing popularity of testing methods is expected to drive the market's growth.

Point-of-care (POC) based testing methods have recently attained massive popularity as these tests provide rapid and accurate results in minimal time. Moreover, these tests can also be easily used in a wide range of healthcare settings. For instance, Abbott's Afinion POC and NycoCard CRP testing methods are suitable for hospital use in the intensive care unit, emergency room, rheumatology, oncology, hematology, and pediatric units of hospitals well as in primary care. Thus, the growing popularity of testing methods is expected to drive the market's growth from the above statements.

The market is expected to hamper due to the availability of alternative treatments with higher accuracy.

CRP High Sensitivity (CRPHS) is a test that measures CRP at low levels. When assessing baseline (i.e., normal) values, CRPHS is more exact than standard CRP, allowing for a measure of chronic inflammation. Moreover, lack of qualified specialists, low demand for C-reactive protein tests compared to other blood tests, and concerns about bad reactions are some factors that the market is expected to get hampered in the forecast period.

COVID-19 Impact Analysis on C - Reactive Protein Test (CRP) Market

The COVID-19 pandemic is expected to impact the C-reactive protein (CRP) market positively. Hospitals in several places are facing significant issues as the number of COVID-19 patients continues to rise rapidly. Severe patients are usually treated in an intensive care unit, whereas moderate patients are admitted to a standard isolation ward. A small percentage of non-severe individuals, however, will progress to severe instances. As a result, reducing mortality and improving outcomes for COVID-19 individuals requires a solution to the problem of identifying this group of patients early and aggressively monitoring and treating them. CRP levels in COVID-19 patients can effectively predict disease severity, adverse outcomes, prognosis, and mortality. High CRP levels in COVID-19 patients at hospital admission indicate CRP can be utilized as an independent biomarker for earlier detection of disease severity. These biomarkers act as an important tool to detect patients on the verge of developing severe disease even before the manifestation of clinical symptoms in those epidemic areas with limited health resources to carry out expensive laboratory and radiological examinations for COVID-19 patients. Therefore, from the above statements, the market is expected to boost in the forecast period.

C - Reactive Protein Test (CRP) Market Segmentation Analysis

The immunoturbidimetric assay segment is expected to hold the largest market share in the C-reactive protein test (CRP) market.

The immunoturbidimetric assay segment accounted for the largest market share in 2020. The wide availability of advanced C-reactive protein determining systems, such as immunoturbidimetric technique-based POC devices and latex-enhanced, high sensitivity systems, attributes to its large revenue share. For instance, Aidan's QuikRead CRP is a rapid and straightforward immunoturbidimetric technique-based POC testing method that determines the protein concentration to support infectious disease diagnosis. Moreover, this essay type offers several advantages, including high speed, ease of automation, and good precision, increasing demand in this segment. In addition, technological advances in immunoturbidimetric tests are projected to drive market expansion in the coming years. Researchers worldwide are working to create advanced and creative assays that will allow for speedy and accurate CRP testing. Researchers at DM Vasudevan Agappe Diagnostic Limited in India, for example, demonstrated the use of a latex-enhanced immunoturbidimetric test for high sensitivity and a wide range of C-reactive protein detection in human serum in a report published in January 2021.

the hs-CRP test type segment is expected to hold the largest market share in the C-reactive protein test (CRP) market.

In 2020, the hs-CRP test type segment accounted for the largest market share. It is attributed to its higher sensitivity than traditional testing methods. It precisely measures low C-reactive protein levels to determine inflammatory levels. Moreover, these characteristics have made determining the risk of cardiovascular disease in healthy patients simple. Besides, current research studies on this test are likely to boost its application in clinical diagnostics, resulting in higher revenue generation in this market.

Furthermore, multiple research studies have demonstrated that hs-CRP assays are increasingly being employed as a marker for various medical disorders, including hypertension, malaria, cancer, and bone illnesses, promoting the adoption of this segment over the others. As a result, the hs-CRP test type is predicted to hold the largest market share in the forecast period.

The cardiovascular disease segment is expected to hold the largest market share in the C-reactive protein test (CRP) market.

In 2020, the cardiovascular diseases (CVD) segment accounted for the largest market share. It is attributed to the rising incidence of CVD globally, increasing the demand for C-reactive protein testing. According to the American Heart Association 2019 data, over 356,000 out-of-hospital cardiac arrests in the U.S. every year, among which 90% of cases are fatal. Moreover, the high incidence rate boosts clinicians to implement C-reactive protein testing on a large scale.

Moreover, the increase in CVD cases helps researchers conduct numerous investigational studies for examining the role of testing C-reactive protein in CVD, thereby improving the segment revenue generation. For instance, a research study by Wei Wang published in August 2019 demonstrated that the ratio of hs-CRP and prealbumin acts as an early biomarker to predict in-hospital major adverse cardiac events in patients. Thus, from the above statements, the cardiovascular diseases segment holds the largest market share.

C - Reactive Protein Test (CRP) Market Geographical Share

North America region holds the largest market share in the global C-reactive protein test (CRP) market

In 2020, North America accounted for the highest revenue share. Established players, technological advancements, well-established healthcare infrastructure, and a well-established reimbursement scenario are some of the factors the region is expected to boost in the forecast period. For instance, BlueCross BlueShield of North Carolina covers CRP measurement in diagnosing inflammatory illnesses as part of its general inflammation testing coverage. According to the Centers for Disease Control and Prevention, CHD also caused 365,744 deaths in the United States in 2018. CHD, on the other hand, claimed the lives of almost 370,900 people this year. Furthermore, the market is predicted to grow in the coming years due to increased public awareness of testing and testing technologies in healthcare. Therefore, from the above statements, the market is expected to boost in the forecast period.

C - Reactive Protein Test (CRP) Companies and Competitive Landscape

Major key players in the C-reactive protein test market include Abbott Laboratories, F. Hoffmann-La Roche AG, Merck KGaA, Randox Laboratories Ltd., BODITECH MED INC., Abaxis, Inc., Thermo Fisher Scientific, Inc., Siemens, Laboratory Corporation of America Holdings, and Beckman Coulter Inc. (Danaher Corporation).